SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple-negative Breast Cancer and HR+/HER2- BC
Interventions: DRUG: SKB264|DRUG: KL-A167
Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.